TRVI
Trevi Therapeutics Inc
13.90$
-1.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Trevi Therapeutics Inc (TRVI) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -17 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.0 | -4.0 | -5.6 | -4.0 | -4.7 | -4.1 | -5.1 | -7.7 | -6.2 | -4.7 | -8.4 | -7.0 | -8.9 | -7.6 | -7.9 | -7.2 | -6.2 | -7.1 | -6.2 | -8.6 | -6.3 | -8.2 | -9.9 | -7.3 | -6.4 | -10 | -8.7 | -9.6 | -9.6 | -13 | -10 | -11 | -7.6 | -17 | -17 | -53 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.4 | 0.4 | 0.7 | 0.6 | 0.6 | 0.5 | 0.7 | 0.7 | 0.5 | 0.5 | 0.7 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.5 | 0.5 | 0.7 | 1.1 | 0.8 | 0.9 | 1.2 | 1.4 | 1.2 | 1.4 | 2.2 | 3.3 | 8.1 | |
| 0.1 | 0.9 | 0.6 | – | 0.3 | 0.2 | 0.4 | 0.4 | 0.4 | 0.7 | 0.6 | 0.6 | 0.5 | 0.7 | 1.1 | 0.5 | 0.5 | 0.7 | 0.5 | 0.6 | 0.5 | 0.6 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | -0.9 | -1.4 | 0.8 | 0.9 | 0.5 | 1.9 | -0.8 | 0.0 | 3.1 | -1.7 | -0.3 | -0.1 | -0.1 | 0.7 | -0.7 | 1.6 | -0.7 | 1.1 | -0.8 | -0.9 | -1.8 | -3.0 | 0.2 | 0.7 | -0.1 | 2.7 | 3.2 | 1.0 | -4.1 | 1.1 | -0.2 | -0.3 | -5.4 | -2.5 | -8.4 | |
| 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13 | 0.0 | 0.0 | 13 | 0.1 | 0.1 | 14 | |
| 0.0 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | -54 | -54 | -54 | -54 | -4.9 | -48 | 9.0 | 20 | 18 | 13 | -8.1 | 2.8 | 7.7 | -24 | -10.0 | -2.6 | -51 | -31 | 17 | -112 | -177 | |
| 0.0 | – | – | – | 0.0 | 1.6 | – | – | 2.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | – | 0.0 | 11 | 10.0 | 61 | -0.1 | 0.1 | – | – | – | – | 0.0 | 0.0 | – | – | 0.0 | 58 | 57 | 2.4 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -2.1 | -2.1 | -2.7 | – | 0.0 | – | – | – | 14 | 14 | 14 | 14 | – | – | -0.6 | -0.6 | -0.6 | -0.6 | -1.8 | -1.8 | -1.8 | -1.8 | -7.7 | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 16 | 0.6 | 4.1 | 2.8 | 0.1 | 14 | -0.6 | 56 | 55 | 0.7 | -1.7 | -7.7 | 1.5 | -0.1 | 0.0 | 5.1 | 5.0 | 51 | 8.7 | 110 | 1.6 | 0.3 | 0.2 | 164 | 166 | |
| 0.0 | -6.1 | -8.9 | 6.5 | -6.3 | 5.7 | 58 | -7.9 | -6.2 | -4.7 | -8.5 | 9.1 | -8.3 | -3.4 | -5.1 | -7.1 | 7.5 | -7.7 | -4.4 | 42 | -54 | -0.9 | 2.1 | 12 | 6.4 | -19 | -0.8 | 3.1 | 18 | -15 | 98 | -60 | -38 | 0.5 | 35 | -63 | |
| 0.0 | -4.0 | -5.6 | -4.0 | -4.8 | -4.1 | -5.1 | -7.7 | -6.2 | -4.7 | -8.4 | -7.0 | -8.9 | -7.6 | -7.9 | -7.2 | -6.2 | -7.1 | -6.2 | -8.6 | -6.4 | -8.3 | -9.9 | -7.3 | -6.4 | -10 | -8.7 | -9.6 | -9.6 | -13 | -10 | -11 | 5.8 | -17 | -18 | -39 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.